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Glioblastoma is the most common primary brain tumor. Standard therapy consists of maximum 
safe resection combined with adjuvant radiochemotherapy followed by chemotherapy with 
temozolomide, however prognosis is extremely poor. Assessment of the residual tumor after surgery 
and patient stratification into prognostic groups (i.e., by tumor volume) is currently hindered by 
the subjective evaluation of residual enhancement in medical images (magnetic resonance imaging 
[MRI]). Furthermore, objective evidence defining the optimal time to acquire the images is lacking. 
We analyzed 144 patients with glioblastoma, objectively quantified the enhancing residual tumor 
through computational image analysis and assessed the correlation with survival. Pathological 
enhancement thickness on post‑surgical MRI correlated with survival (hazard ratio: 1.98, p < 0.001). 
The prognostic value of several imaging and clinical variables was analyzed individually and combined 
(radiomics AUC 0.71, p = 0.07; combined AUC 0.72, p < 0.001). Residual enhancement thickness and 
radiomics complemented clinical data for prognosis stratification in patients with glioblastoma. 
Significant results were only obtained for scans performed between 24 and 72 h after surgery, raising 
the possibility of confounding non‑tumor enhancement in very early post‑surgery MRI. Regarding 
the extent of resection, and in agreement with recent studies, the association between the measured 
tumor remnant and survival supports maximal safe resection whenever possible.
Abbreviations
AUC  Area under the curve
CI  Confidence interval
DSC  Dynamic susceptibility contrast
EPMR  Early post-operative magnetic resonance
HR  Hazard ratio
IDH  Isocitrate dehydrogenase
KPS  Karnofsky performance status
LR  Likelihood ratio
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PSR  Percentage of signal recovery
rCBV  Relative cerebral blood volume
ROI  Region of interest
OS  Overall survival
VOI  Volume of interest
W  Weighted
Glioblastoma is the most common primary brain  tumor1. Although some treatments prolong survival, the 
prognosis of patients with glioblastoma is very poor, e.g. 2-year survival of 26.5%2. Standard of care therapy 
consists of maximum safe resection combined with adjuvant radiochemotherapy followed by chemotherapy with 
temozolomide. The extent of tumor resection is a relevant prognostic factor in this patient  population3–9. Albert 
et al.established that the extent of resection should be evaluated with a magnetic resonance imaging (MRI) scan 
performed shortly after surgery, as inflammatory reparative changes can result in benign non-tumor contrast 
enhancement that can be misinterpreted as tumor  remnants10. This is widely accepted in clinical practice, and 
most guidelines recommend performing early postoperative magnetic resonance (EPMR) to evaluate the extent 
of resection. Some guidelines suggest performing the EPMR scan within the first 72 h after surgery, while others 
are more restrictive and state with 48 h11–13. However, these recommendations rely on the experience and opinion 
of experts, rather than on formal clinical evidence. To the best of our knowledge, an in-depth evaluation of the 
optimal time range to perform the EPMR scan has not yet been described. An objective numerical assessment 
of the residual tumor enhancement to support this would allow identification of the optimal timing to evalu-
ate the enhancement in the EPMR, and thus, the timing at which it is most informative for patient prognosis.
There is no consensus about the extent of resection to stratify prognostic groups. Some studies suggest 
an “all-or-nothing”  approach8 in which complete resection should be achieved to improve patient survival. 
However, others suggest that it is possible to stratify several prognostic groups according to ranges of tumor 
 resection3–7,9,10,14,15, namely < 75%, 75–95%, 95–100% and total resection.
An objective numerical evaluation of the residual tumor would allow analysis of a continuous range of values 
instead of subjective qualitative assessment, and help identify the best approach in regards to therapy and prog-
nosis, while also being readily applicable and comparable between centers and studies. In this study, we focus 
on the enhancing residual tumor only. While there may be also non-enhancing residual tumor, a recent study 
has demonstrated an association between the post-operative enhancement volume and  survival16. Therefore, 
it may be possible to identify additional prognosis value using more extensive image analysis of the enhancing 
tumor remnant in the post-surgical MRI. To this end, we focused on the post-surgical MRI and investigated 
radiomics and perfusion imaging features as an alternative evaluation to the extent of resection, which requires 
paired pre- and post-surgical MRI.
Image processing and radiomics extract quantifiable features from body tissues using characterization algo-
rithms on the image spatial data. Radiomics is a lively topic of research that is shaping medical image assessment 
and interpretation, providing crucial information regarding tumor biology including  glioblastomas17,18.
In this study, our goals were to develop a tool to facilitate the quantification of enhancing post-surgery 
residual tumor in patients with glioblastoma and analyze whether precise quantification of the area of contrast 
enhancement by image processing and radiomics could improve the patient´s prognostic evaluation. With this 
objective data, we also assessed the time range from surgery to the EPMR scan for an optimal association of 
residual tumor and overall survival (OS), to provide quantitative evidence for the optimal time range to perform 
the EPMR scan after surgery.
Results
A total of 144 patients were included in the study (92 [64%] men, 52 [36%] women); median age of all patients 
was 59 years (range 20–77 years). Population demographics are described in Supplementary Table S1.
Correlation of post‑operative enhancement with survival. The enhancement thickness was calcu-
lated as the 3D distance transform of the segmented tumor, and mean and maximum values were determined. 
The mean and maximum enhancement thickness correlated with OS with a hazard ratio (HR) of 1.98 (95% 
CI 1.36–2.90, p < 0.001) and 1.11 (95% CI 1.05–1.17, p < 0.001), respectively (Table  1). Mean and maximum 
thickness also correlated significantly with progression-free survival (PFS) with HR of 2.01 (95% CI 1.35–3.12, 
p < 0.001) and 1.08 (95% CI 1.03–1.14, p = 0.004), respectively.
The survival rate of patients with a mean thickness of 1.4 mm or more was 47% after 12 months, whereas 
survival of patients with a mean thickness less than 1.4 mm was 78% (p < 0.001, Fig. 1, left panel). Similarly, the 
survival rate of patients with a maximum thickness of 8 mm or more was 55% after 12 months, whereas survival 
of patients with maximum thickness of less than 8 mm was 80% after 12 months (p = 0.0012, Fig. 1, right panel).
The volume of enhancement was also associated with OS, with an HR of 1.04 (95% CI 1.01–1.07, p = 0.009), 
however there was no significant association with PFS (HR 1.02, 95% CI 0.99–1.05, p = 0.19). A previously 
reported threshold of 12 mL16 resulted in unbalanced subpopulations: patients with enhancement volume greater 
than 12 mL (n = 10) had a survival rate of 20% at 12 months, while patients with volume less than 12 mL 
(n = 134) had a survival rate of 75% at 12 months (Supplementary Fig. S1). Despite the different survival rates, 
Kaplan–Meier analysis did not yield a significant difference (p = 0.1).
Survival prediction for time between surgery and the EPMR scan. We analyzed the population 
in terms of the time elapsed between surgery and the EPMR scan according to the following groups: within 
24 h (n = 26), from 24 up to 48 h (n = 51), from 48 up to 72 h (n = 42), and 72 h or more (n = 25). The mean and 
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maximum thickness of enhancement were significantly associated with survival in patients with an EPMR scan 
performed between 24 and 72 h after surgery (p < 0.05, adjusted for multiple test comparisons, Table 1). There 
was no association between thickness and OS when the EPMR was performed within 24 h of surgery or more 
than 72 h after. In Supplementary Fig. S2, the HR and the confidence intervals of each subgroup are shown for 
comparison, and the Kaplan–Meier curves are shown in Supplementary Fig. S3.
Prognostic value of perfusion sub‑analysis. Dynamic susceptibility contrast (DSC) data were available 
for 113 patients (113/144, 78%). When the entire population was analyzed, patients with a relative cerebral blood 
volume in the 99th percentile (rCBV-99) above 8.26 had worse survival (p = 0.05, Supplementary Table S2), with 
a survival rate of 50% after 12 months, compared to a 75% rate in patients below this threshold (Supplementary 
Fig.  S4). A maximum percentage of signal recovery (PSR) above 112% defined patients with lower survival 
(p < 0.001, Supplementary Table S2), with a 50% survival rate after 12 months, compared to an 80% rate for 
patients below the threshold (Supplementary Fig. S4).
We also analyzed the perfusion data in terms of the time between surgery and the EPMR scan, according to 
within the first 24 h (n = 22), between 24 and 48 h (n = 37), between 48 and 72 h (n = 33) and 72 h or later (n = 21). 
rCBV-99 predicted survival when the EPMR scan was performed 24 to 48 h post-surgery (p = 0.004 adjusted for 
multiple test comparisons, Supplementary Table S2); for patients with a rCBV-99 above 7.93, the survival rate 
was 20% after 12 months, compared to 70% for those below this threshold (Supplementary Fig. S4). The maxi-
mum PSR predicted survival when the EPMR scan was performed 24 to 72 h post-surgery (p < 0.001, adjusted 
for multiple test comparisons, Supplementary Table S2), with a survival rate of 20% after 12 months for patients 
above a 111% threshold and a rate of 80% for patients below this threshold (Supplementary Fig. S4). Neither 
the rCBV-99 nor PSR had prognostic value when the EPMR scan was performed within 24 h of surgery. When 
Table 1.  Univariate Cox model of the enhancement thickness (mean and maximum) for overall survival, for 
the entire population and by subgroup according to time elapsed between surgery and the MRI. P-values were 
adjusted for multiple test comparison. N number of observations, SD standard deviation, mm millimetres, h 
hour, HR hazard ratio, CI confidence interval, LR likelihood ratio.
Variable Group
Distribution Cox regression
n Mean SD HR 95% CI p-value
Mean thickness (mm)
All 144 1.18 0.44 1.98 1.36–2.90  < 0.001
 < 24 h 26 1.25 0.57 1.19 0.59–2.39 0.44
24–48 h 51 1.18 0.39 3.00 1.24–7.24 0.03
48–72 h 42 1.16 0.44 3.30 1.30–8.40 0.03
 ≥ 72 h 25 1.21 0.51 2.40 0.74–7.72 0.16
Maximum thickness (mm)
All 144 7.16 3.27 1.11 1.05–1.17  < 0.001
 < 24 h 26 6.98 3.54 1.02 0.91–1.14 0.56
24–48 h 51 7.41 3.23 1.21 1.08–1.36 0.005
48–72 h 42 6.92 3.05 1.19 1.04–1.36 0.02
 ≥ 72 h 25 7.16 3.81 1.08 0.96–1.21 0.21
Figure 1.  Kaplan–Meier survival curves for the enhancement thickness analysis, according to high and low 
mean (left) and maximum (right) thickness. Censored data are indicated with tick marks.
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the scan was performed more than 72 h after surgery, the rCBV-99 showed significantly different survival rates 
(p = 0.011), albeit with unbalanced subgroups.
Prognostic value of the radiomics signature. The population with measurable enhancement segmen-
tation (129/144, 90%; see “Methods” for details) was analyzed to determine the prognosis of the clinical endpoint 
of OS ≥ 2 years (long; 36/129, 28%) or OS < 2 years (short; 93/129, 72%). The population was randomly split into 
training (92/129, 70%) and test (37/129, 30%) sets, with balanced distribution of survival in both sets (26/92, 
28% of long survivors in the training; 10/37, 27% of long survivors in the test set) (Supplementary Table S3).
Twelve radiomics variables were selected in the training set using minimum-redundancy-maximum-relevance 
and stepwise regression (Supplementary Table S4). This radiomics signature predicted short and long survival 
groups with an AUC of 0.73 (0.60–0.86 p < 0.001) in the training set and an AUC of 0.71 (0.55–0.88 p = 0.01) in 
the test set. Receiver operating characteristic (ROC) curves and Kaplan–Meier curves of the training and test 
sets are presented in Supplementary Fig. S5.
Combining quantitative imaging and clinical data for predicting survival. The multivariate logis-
tic model including all imaging features (mean enhancement thickness, DSC, radiomics) and clinical data (age, 
postoperative KPS) yielded the highest prognostic capacity for predicting long and short survival (AUC 0.72, 
95% CI 0.61–0.83, p < 0.001, Fig. 2). In the multivariate Cox model including all of these parameters, the mean 
thickness and age were retained as independent prognostic factors (Supplementary Table S5).
Discussion
Radiological visual assessment of the remaining tumor after surgery is the standard of care in oncology clinical 
practice, and should be performed with an MRI rapidly after the surgical procedure. The extent of resection is 
a well-known prognostic factor in  glioblastomas4,5,8, though inter-reader reproducibility is limited and hinders 
comparisons between centers and studies.
In this study, we identified a method to facilitate the quantification of the remaining tumor using a processing 
pipeline of multi-sequence MRI scans. By automatic registration and subtraction of T1w and T1wC images, it 
is possible to optimally isolate the enhancing areas from confounding post-operative changes. This method was 
also conceived by Ellingson et al.16, although they reported only the enhancement volume and did not analyze 
the influence of time to the EPMR, to measure post-surgery residual enhancing tumor. Moreover, we analyzed 
and internally validated a multivariate prognostic model including quantified residual tumor, perfusion, radiom-
ics and clinical variables in an effort to improve the prognostic performance of residual tumor enhancement.
In our population, the quantification of the residual enhancement thickness after surgery shows a continuous 
association with OS and PFS (HR of 1.98 and 2.01 respectively, for mean enhancement thickness) that outper-
forms the subjective assessment of a dichotomous thin-or-thick tumor  remnant3. Our findings also showed that 
the enhancement thickness had a stronger association with survival compared to the enhancement volume, 
suggesting the value of further investigation of this metric.
Figure 2.  ROC of different prognostic models: perfusion variables (99th percentile cerebral blood volume 
[rCBV], maximum percentage of signal recovery [PSR]), mean thickness of enhancement and all variables 
(perfusion, thickness, age, Karnofsky performance status [KPS] and radiomics) together for predicting survival 
(left panel). The model with clinical variables age and KPS is shown in the right panel for clarity.
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The combination of the enhancement thickness, perfusion, radiomics and clinical data into a predictive 
model showed slightly better performance (AUC 0.72) for distinguishing patients with short and long survival 
compared to thickness alone, compared to the univariate perfusion or the clinical models. When analyzed in 
separate groups, age and KPS yielded the lowest AUC (0.59), followed by rCBV and PSR (0.60), thickness (0.61) 
and radiomics (0.71). Therefore, in our population, radiomics variables performed better when applied in a 
dichotomous patient longer-or-shorter survival model, while the other variables added only marginal value. 
However, when correlating with specific patient survival, enhancement thickness alone demonstrated mean-
ingful prognostic value, with higher mean thickness (as a continuous variable) associated with poorer survival 
(HR of 1.98 [95% CI 1.36–2.90, p < 0.001]). Both the enhancement thickness and the radiomics signature can be 
automatically calculated from the enhancement mask. Although further work is needed to facilitate the imple-
mentation of these assays in clinical practice, these results show the potential application of quantitative data 
from EPMR T1w and T1wC for supporting medical decisions.
We also explored the impact of the time between surgery and the MRI scan for quantifying the residual 
tumor. According to the National Comprehensive Cancer Network guideline, the early post-surgery MRI scan 
should be performed within the first 72 h after  surgery19. Other guidelines are more restrictive and suggest that 
the scan be performed within the first 24 to 48 h after  surgery12,13,20. The rationale for earlier imaging is that 
after 72 h post-surgery, inflammatory reparative changes result in benign non-tumor contrast enhancement that 
could be misinterpreted as tumor  remnant10. Correspondingly, in our study we found no significant association 
between the measured enhancement and OS in the group of patients with EPMR scans performed more than 
72 h after surgery.
Interestingly, we found no association between the enhancement thickness and survival when the MRI was 
acquired within the first 24 h after surgery. Although the sample size of this subpopulation was small (n = 26 
patients), there was no visible trend towards the strong association found for the next time range. We hypothesize 
that immediately after surgery, intra-cavity transudation leads to non-tumor enhancement. Accordingly, Smets 
et al. showed that contrast transudation could appear in the very early postoperative MRI scans of  glioblastomas6. 
Thereafter, the tissues may repair so that the enhancement corresponds to the real tumor remnants. Nevertheless, 
other possible explanations for this lack of association include the presence of surgical products that may affect 
MRIs performed soon after surgery.
We further explored whether features describing tissue vasculature from the DSC would differentiate the 
enhancement corresponding to post-surgery residual tumor and inflammation. Interestingly, 99th percentile 
rCBV and maximum PSR are indicators of bad prognosis when the residual tumor was assessed in an EPMR 
performed more than 24 h post-surgery. Accordingly, associations between recurrent tumor and higher rCBV 
values have been previously  reported21. However, this correlation is strongest between 24 to 48 h but was not 
present for scans acquired before 24 h or after 72 h.
Taken together, these findings suggest that the enhancement thickness is representative of the remaining 
tumor when the MRI scan is acquired from 24 to 72 h after surgery, however there may be some confounders 
(i.e., non-tumor contrast enhancement) when the EPMR is acquired too early (during the first day after surgery) 
or too late (more than 4 days after surgery). Further studies are needed to better ascertain the importance of the 
number of days after surgery in measuring the remaining tumor tissue and elucidating the biological explana-
tion behind such a phenomenon.
The prognostic value of the extent of resection is widely accepted by the scientific community. Nevertheless, 
there is no consensus about the threshold of the extent of resection that can influence survival. Some authors 
have suggested an “all-or-nothing”  approach8. In this setting, no debulking surgery should be pursued when 
the tumor involves critical brain areas. Other studies however, suggest that a smaller extent of tumor resection 
could also positively impact patient  survival3–7. In agreement with this, we found a correlation between residual 
tumor extent and patient survival. This supports maximal safe tumor resection with the knowledge that it could 
improve patient survival even in cases of partial tumor resection.
In our population, the radiomics analysis of the enhancement area including texture features, allows for 
identification of patients with long and short survival. As previously shown, radiomics features inform tumor 
heterogeneity and are indicators of tumor aggressiveness in  glioblastoma22–24. We have explored several other 
variables to evaluate their clinical utility. While all quantitative imaging data (radiomics, thickness, DSC) provide 
relevant information that complements clinical data (age and KPS), we found the enhancing tumor thickness 
and radiomics to have high prognostic value and only T1w and T1wC are required to calculate them, thus sim-
plifying the implementation.
This study has a number of potential limitations. Firstly, as a retrospective study, isocitrate dehydrogenase 
(IDH) mutation status data were available for 54 patients, only one of whom (2%) had an IDH mutation. This 
low incidence rate may be explained by the relatively old age of our population, as IDH-mutant glioblastoma has 
been reported to correlate with younger  age25. In addition, only glioblastomas treated with maximal safe resec-
tion were included in our study. Newly diagnosed IDH-mutant glioblastoma tend to present with a more diffuse 
infiltrative pattern than IDH-wildtype glioblastoma, likely leading to a biopsy instead of a maximal safe resection, 
and IDH-mutant glioblastomas progressing after a previous known IDH-mutant low-grade  astrocytoma26 were 
also not included in our study. Therefore, there may be confounders in patients for whom IDH status is missing, 
although as the rate of IDH mutant in glioblastoma is 10% in the general  population27 compared to approximately 
2% in our population, we believe this did not significantly affect our results.
Secondly, in this analysis we focus on the post-surgical residual enhancing tumor and certain drugs may be 
administered perioperatively that can affect the enhancement on post-surgery T1wC scans (i.e., glucocorticoids 
or antiangiogenic drugs such as bevacizumab). We confirmed that bevacizumab was not administered prior to 
EPMR in any patients. Glucocorticoids might have been administered in cases with extensive edema, which could 
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have influenced the characteristics of post-contrast MRI. Nevertheless, glucocorticoids are avoided as much as 
possible in our hospital to prevent this drug from affecting the histological interpretation of biopsy samples.
Thirdly, given the observational retrospective nature of this study, standardization of all the image acquisition 
parameters was not possible. Therefore, all images were homogenously normalized in intensity and resampled 
to minimize variability. Additionally, DSC scans without contrast preload and acquisition at 1.5 T may result in 
leakage effects, hence leakage correction methods were applied to avoid confounders. Additionally, the method 
used requires input (semi-automatic segmentation) from an experienced radiologist who supervises the enhance-
ment mask. This might induce some segmentation variability. However, the thickness is calculated as the mean 
value of the distance transform, and thus it is possible that an average value smooths out small differences in 
segmentations, making it more robust. Lastly, we performed an internal validation, though applying the prog-
nostic models to an external dataset would confirm its performance.
It is noteworthy to mention that there may still be non-enhancing residual tumor, which is out of the scope 
of the current analysis. Therefore, as future work, combining other sequences such as T2w and FLAIR (Fluid-
Attenuated Inversion Recovery) may be useful to delineate additional areas of residual tumor with a potential 
role in patient  prognosis28,29, although at the expense of a more complex pipeline.
Additionally, novel MRI techniques using chemical exchange saturation transfer (CEST) imaging have been 
reported to correlate with response to treatment and survival. With CEST MRI, pulses off the water resonance 
frequency are absorbed by proteins that then transfer the energy to water through chemical exchange, lowering 
the signal. Derived signal maps such as amide proton transfer (APT) and nuclear Overhauser effect (NOE) are 
both reported to correlate with survival in gliomas and  glioblastomas30–32, even in a sub-cohort of IDH-wildtype 
patients. While the number of patients evaluated in these studies is small, they showed similar HRs as those 
reported in our study. This highlights the potential of CEST MRI and its radiomics analysis, and merits further 
research. In combination with the relevant variables proposed in this study, a thorough imaging signature could 
provide major insight into patient response.
In conclusion, in patients with glioblastoma multiforme, objective quantification of the area of enhancement 
in the tumor bed after surgery, in an EPMR scan performed between 24 and 72 h after surgery provides relevant 
information on the remaining tumor and relevant prognostic information. The MRI processing pipeline defined 
in this study is an easy and rapid method for a more accurate evaluation of the post-surgery residual tumor, that 
could be implemented in routine clinical practice.
Methods
Ethical approval. The Research Ethics Committee of the Hospital Universitari de Bellvitge revised and 
approved this study, in compliance with applicable regulatory requirements and the International Conference 
on Harmonization Guidelines on Good Clinical Practice (ICH GCP). For this retrospective study, informed 
consent was waived by the Research Ethics Committee of the Hospital Universitari de Bellvitge.
Study population and design. We evaluated data from 160 consecutive patients with primary glioblas-
toma multiforme who underwent maximum safe resection surgery between February 2009 and December 2017 
at the Hospital Universitari de Bellvitge, Spain, and who had an early post-surgery MRI scan (i.e., within the 
first week after surgery). Data on isocitrate dehydrogenase (IDH) 1/2 mutation status were available in 54 out of 
160 patients (33%)33. Only one patient (1/54, 2%) had an identified IDH mutation. To be eligible for the analysis, 
patients had to have been treated with adjuvant radiotherapy plus concomitant and post-radiotherapy temozo-
lomide (i.e., Stupp protocol)2 (144/160, 90%).
MRI scan protocol and image pre‑processing. The earliest post-surgery MRI scan per patient was col-
lected, including T1-weighted before (T1w) and after intravenous contrast administration (T1wC), and dynamic 
susceptibility contrast (DSC) images. Approximately half of the MRI scans were acquired with a 1.5  T MR 
magnet Intera (Philips Healthcare, Best, The Netherlands) and half with a 1.5 T MR magnet Achieva (Philips 
Healthcare, Best, The Netherlands) with the following parameters for T1w: spin-echo; TE 15 ms; TR 540 ms; flip 
angle 90°; matrix size 256 × 256  mm2; slice thickness 5 mm.
A single MRI scan was performed with a 3 T MR unit (Achieva; Philips Healthcare, Best, The Netherlands), 
gradient-echo; TE 4 ms; TR 9 ms; flip angle 8º; matrix size 672 × 672  mm2; slice thickness 1 mm.
Regarding DSC, all acquisitions were gradient-echo without bolus preload; a total of 10 baseline points were 
collected before the pass of contrast with the following protocol: in the 1.5 T Intera MR unit (scans from 2009 to 
2015) PRESTO sequence; TE 25 ms; TR 17 ms; flip angle 7°; matrix size 128 × 128 mm2; slice thickness 3.5 mm; 
dynamic acquisitions 40. In the 1.5 T Achieva MR unit (from 2015 to 2917) TE 40 ms; TR 1522–1642 ms; flip 
angle 75º; matrix size 128 × 128 mm2; slice thickness, 4–5 mm; dynamic acquisitions 60.
A single MRI scan was performed with a 3 T MR unit (Achieva; Philips Healthcare, Best, The Netherlands), 
echo planar sequence; TE 40 ms; TR 1618 ms; flip angle 75º; matrix size 128 × 128  mm2; slice thickness 4 mm; 
dynamic acquisitions 40.
The pre-processing of images for homogenization included N4 bias field  correction34 and intensity normaliza-
tion with Nyul’s method as adapted by  Shah35,36.
Enhancement mask definition and thickness quantification. The T1w and T1wC images with dif-
ferent slice spacing (1/144 = 1% of the scans) were resampled to 5 mm for consistency and robustness. The T1w 
was registered to the T1wC with the rigid transformation tool of 3DSlicer v4.1037. The T1w signal intensity was 
normalized to that of the  T1Cw28. A 3D enhancement map was obtained by T1w-T1wC subtraction. The area of 
enhancement within and around the tumor bed was delineated by an experienced radiologist (P.N.B), blinded 
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Figure 3.  Pipeline of the applied methods. Registration is performed with the contrast-T1w scan as the 
reference image and the radiomics features are extracted from the contrast-T1w. The thickness is calculated 
from the 3D distance transform of the volume of interest, depicted as a colormap.
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to the clinical outcome, using the 3DSlicer semi-automatic delineation tools (thresholding and morphological 
operations).
The 3D distance transform of the volume of interest (VOI) was then calculated. The distance transform 
provides the Euclidean distance in millimeters of every voxel within the VOI to its nearest VOI  boundary38. We 
calculated the mean and the maximum values of the 3D distance transform as measures of the enhancement 
mask thickness for each patient (Fig. 3), as well as the total volume of the VOI.
Perfusion MRI sub‑analysis. The DSC temporal volumes were processed with the DSCMRIAnalysis mod-
ule of  3DSlicer37,39, the curves were leakage-corrected with the Boxerman–Schmainda–Weiskoff  method40 and 
the rCBV were obtained. The DSC volumes were then registered to the T1wC images for co-alignment with the 
enhancement masks. The temporal curves of the DSC were first analyzed to remove noisy and low-signal curves 
from the mask. For this purpose only, the curves were low-pass filtered, normalized between − 1 and 0, and then 
those that reflected the bolus  arrival41,42 were selected by resemblance to a Gaussian distribution (Supplementary 
Fig. S6). Once the DSC curves had been filtered, the original non-normalized DSC values were analyzed.
Relative cerebral blood volume. An ROI within the white matter contralateral to the tumor was deline-
ated in each MRI and the relative cerebral blood volume (rCBV) map was normalized to this ROI. To retrieve the 
tumor hot-spot, we calculated the 99th percentile of the rCBV (rCBV-99) and the maximum percentage of signal 
recovery (PSR) from the enhancement mask selected curves. The rCBV-99 and not the maximum was calculated 
to avoid extreme outlier values of the rCBV. The PSR was calculated as described by Cha et al.42.
Radiomics feature extraction and robustness. Radiomics extraction was performed with Pyradiom-
ics v2.1.2 for  Python43, with image resampling of 1 mm isotropic voxels and fixed binarization to 10 levels of bin-
width, as has been suggested to maximize radiomics  reproducibility44–46. Ninety-four radiomics features were 
extracted from the enhancement mask applied to the T1wC images, including first-order (n = 19) and second-
order from texture Grey-Level Co-occurrence Matrix (n = 24), Grey-Level Run-Length Matrix (n = 16), Grey-
Level Size-Zone Matrix (n = 16), Neighboring-Grey-Tone Difference Matrix (n = 5) and Grey-Level Dependence 
Matrix (n = 14) (Supplementary Table S6). Feature description and compliance with image biomarker standardi-
zation initiative guidelines is publicly available in the package  documentation43. We also studied the variability of 
radiomics when changing the extraction parameters voxel size and bin width, and when the most robust features 
(i.e., < 20% coefficient of variation) were selected for further analysis (54 out of 94 [57%] radiomics features, see 
Supplementary Methods).
Radiomics feature selection and analysis. Patients with measurable enhancement segmentation 
(129/144, 90%) were eligible for this analysis. For clarification, these patients may present gross total resec-
tion, however benign reactive enhancement has been reported by some authors up to 72 h after  surgery3,6,16,47. 
The patients were split into ‘training’ (70%) and ‘test’ (30%) sets for internal validation, with balanced survival 
distribution in both sets. Patient characteristics of the sets are presented in Supplementary Table S3. The radi-
omics features were normalized according to the mean value and standard deviation of the training set. From 
the 54 robust features of the previous section, further selection was performed in the training set by minimum-
redundancy–maximum-relevance48,49 plus stepwise regression. The logistic regression model with the selected 
variables was then internally validated in the test set.
Statistical analysis. Log-rank analysis on Kaplan–Meier data and Cox proportional hazards regression 
models were used to evaluate the association of the analyzed variables with survival.
For dichotomized survival analysis, the population was split according to lower or higher than 2-year overall 
survival (< 2 years, ≥ 2 years respectively, Supplementary Table S1). Censored patients with a survival shorter 
than the defined endpoint were excluded. These survival groups were defined for logistic regression models and 
to obtain the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. A threshold for 
each independent variable was calculated from the regression models from the maximum sum of sensitivity and 
specificity (Youden’s index). The postoperative Karnofsky performance status (KPS) was dichotomized as < 90 
and ≥ 90.
To assess how the time from surgery to the EPMR scan affects the residual tumor quantification, sub-analyses 
of survival prediction were performed based on the time elapsed between surgery and the EPMR scan. The 
patients were split into four subpopulations according to the time between surgery and the MRI scan (< 24, 24 
to < 48, 48 to < 72 and ≥ 72 h). Multiple comparison tests were adjusted with the Benjamini–Hochberg method, 
and p-values were considered statistically significant below 0.05.
The thickness analysis was done in-house with Matlab R2015a (Mathworks). Radiomics selection and statisti-
cal analysis were performed with R Statistical Software v3.5.150.
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